Keryx (KERX) Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex
Tweet Send to a Friend
Keryx Biopharmaceuticals (Nasdaq: KERX) announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
